Abstract. The loss of insulin secretion in type I diabetes mellitus (T1DM) is caused by autoimmune-mediated destruction of insulin-producing pancreatic β-cells. Inflammatory cytokines and immune cell infiltration activate oxidative and endoplasmic reticulum (ER) stress, resulting in reduced β-cell viability. The current pharmacological agents used to control blood glucose have a limited effective duration and are accompanied by strong side effects. Blocking the inflammatory and immune responses that cause the β-cell damage has been investigated as a novel therapeutic approach to control T1DM. Icariin is a flavonoid component of Chinese medicinal herbs that has anti-inflammatory effects in vitro and in vivo. The results of the present study revealed that icariin abrogates the pro-apoptotic effect of inflammatory cytokines and significantly suppresses the activation of nuclear factor (NF)-κB in rat pancreatic β-cell lines. The present study may provide a basis for the potential use of icariin as a therapeutic agent for T1DM.
Introduction
The incidence of diabetes mellitus (DM), a complex metabolic disorder associated with defective insulin secretion and activity, has been increasing worldwide over the past 20 years (1, 2) . According to the World Health Organization estimation, ~7% of the world's adult population is diabetic and the diabetic population is likely to increase to ≥300 million by the year 2025 (3). Type 1 DM (T1DM) is an organ-specific autoimmune disease associated with failure to distinguish self-from non-self-antigens (4) . It is caused by T cell-mediated destruction of insulin-producing pancreatic β-cells (4) . The incidence of T1DM is increasing steadily by 3% annually and has a concordance rate of 40-60% for monozygotic twins (4) . As such, environmental and genetic factors may contribute to disease onset (5-7). Currently, insulin therapy is the primary treatment for T1DM. However, tight glycemic control is difficult to achieve in a number of patients, leading to long-term vascular damage associated with kidney failure, heart disease, retinopathy and neuropathy (8) . Recent advances in pancreatic islet transplantation and partial or whole pancreas transplantation represent alternate treatment options for T1DM (9) . However, due to the limited number of organs available for transplant, this approach is not widely used (9) . Since β-cell damage is crucial to the development of T1DM, treatments that are able to prevent β-cell damage may slow disease progression.
Pancreatic β-cell damage is known to be mediated by the immune response (10) (11) (12) . Previous studies have suggested that inflammatory cytokines and immune cell infiltration activate oxidative and endoplasmic reticulum (ER) stress and damage β-cell viability (10) (11) (12) (13) (14) (15) (16) . In the early stages of disease, the infiltration of inflammatory cells promotes the release of cytokines, including interleukin-1β (IL-1β), tumor necrosis factor-α (TNF-α) and interferon-γ (IFN-γ) (15) (16) . IL-1β, alone or in combination with TNF-α or IFN-γ, upregulates the expression of inducible nitric oxide synthase (iNOS) and promotes the generation of nitric oxide (NO) in pancreatic islets (17, 18) . Excessive NO production leads to dysfunctions of mitochondrial metabolism, protein modification and DNA cleavage, which may contribute to the impairment of insulin secretion and triggering β-cell death (19) .
Considering the inflammatory nature of T1DM, it is plausible that anti-inflammatory agents may have potential as anti-DM drugs. Icariin is a naturally occurring flavonoid isolated from traditional Chinese medicinal herbs of the Epimedium genus (20) . The compound has been revealed to have anti-inflammatory, antidepressant, male reproductive, antineoplastic, bone-healing and neuroprotective effects (20) . Early in vivo and in vitro studies revealed that icariin acts as a natural anti-inflammatory drug via multiple mechanisms targeting pro-inflammatory cytokines (TNF-α and IL-6), inflammatory mediators (NO) and adhesion molecules (CD11b) (21, 22) . Xu et al (23) reported that icariin activates the phosphoinositide 3-kinase (PI3K)/protein kinase B (Akt) signaling pathway to ameliorate lipopolysaccharide (LPS)-induced acute inflammatory responses. The known anti-inflammatory effects of icariin suggest that it may inhibit inflammation-induced β-cell death. The aim of the present study was to use rat pancreatic β-cell lines as an in vitro model to investigate the role of icariin. The results suggest that icariin inhibits cytokine-induced NF-κB activation and prevents β-cell death.
Materials and methods
Cell culture. Rat pancreatic β-cell RINm5F cells were obtained from ATCC (Manassas, VA, USA). Cells were cultured in RPMI-1640 medium (Hyclone; GE Healthcare Life Sciences, Logan, UT, USA) with 10% (v/v) heat-inactivated fetal bovine serum (FBS; Gibco; Thermo Fisher Scientific, Inc., Waltham, MA, USA), 2 mM glutamine (Sigma-Aldrich; Merck KGaA, Darmstadt, Germany), 1% non-essential amino acids (Sigma-Aldrich; Merck KGaA), 100 U/ml streptomycin and 100 U/ml penicillin (Sigma-Aldrich; Merck KGaA) at 37˚C in an atmosphere containing 5% CO 2 . Icariin was purchased from Sigma-Aldrich (Merck KGaA). Rat IL-1β and IFN-γ proteins were obtained from R&D Systems (Minneapolis, MN, USA).
MTT assay. MTT (Sigma-Aldrich; Merck KGaA) was used to determine cell viability according to the manufacturer's protocols. Briefly, 5 ml MTT solvent (Beyotime Institute of Biotechnology, Haimen, China) was used to dissolve 25 mg MTT to form an MTT solution at 5 mg/ml. A total of 10 µ1 MTT solution was added to each well and incubated for 4 h at 37˚C in an incubator. Subsequently, 100 µl formazan solution (Beyotime Institute of Biotechnology) was added for 4 h at 37˚C. The optical density of viable cells was measured using a microplate reader (BMG Labtech GmbH, Ortenburg, Germany) at a wavelength of 570 nm.
NO measurement. Biologically synthesized NO is quickly oxidized to form nitrite and nitrate in aqueous solutions (19) . Therefore, detecting the nitrite concentration in cell-free culture supernatants using a colorimetric assay may be indicative of NO generation. In brief, RINm5F cells (5x10 6 ) or 30 islets were treated with the 5 or 10 µM concentrations of icariin for 3 h, prior to being treated with IL-1β (1 U/ml) and IFN-γ (100 U/ml) for 24 h. Subsequently, 100 µl aliquots of culture supernatant were incubated at room temperature for 5 min with 100 µl modified Griess reagent in a 1:1 mixture of 1% sulfanilamide in 30% acetic acid and 0.1% N-(1-naphthyl) ethylenediamine dihydrochloride in 60% acetic acid (Beyotime Institute of Biotechnology). The absorbance was measured at 540 nm. The NO concentration was calculated from the linear standard curve of serial dilutions of sodium nitrite in a working medium.
Reverse transcription-quantitative polymerase chain reaction (RT-qPCR).
Total RNA was extracted from cultured cells using TRIzol reagent (Thermo Fisher Scientific, Inc.). The primer for iNOS was synthesized based on the following previously published sequences (24) : Forward, 5'-GAA TCT TGG AGC GAG TTG TGG-3' and reverse, 5'-AGGA AGT AGG TGA GGG CTT GG-3'. First-strand cDNA was obtained using Super M-MLV Reverse transcriptase (BioTeke Corporation, Beijing, China). Reverse transcription was performed at 42˚C for 15 min and 72˚C for 2 min according to the manufacturer's protocols. PCR was performed using SYBR-Green master mix (Beijing Solarbio Science & Technology Co., Ltd., Beijing, China). The following thermocycling conditions were used: Predenaturation at 95˚C for 30 sec followed by 40 cycles of amplification at 95˚C for 5 sec and annealing and extension at 60˚C for 30 sec. GADPH was used to normalize iNOS mRNA expression. GAPDH forward, 5'-GAT GAC CTT GCC CAC AGC CT-3' and reverse, 5'-ATC TCT GCC CCC TCT GCT GA-3'. The 2 -∆∆Cq method was used to quantify data (24) . ABI Prism 7000 software (Applied Biosystems; Thermo Fisher Scientific, Inc.) was used to analyze data.
Western blotting. Following treatment, proteins were extracted from RINm5F cells using a Nuclear and Cytoplasmic Protein Extraction kit (cat. no. P0027; Beyotime Institute of Biotechnology). Protein concentrations were determined using an Enhanced BCA Protein Assay kit (cat. no. P0010S; Beyotime Institute of Biotechnology). A total of 20 µg/lane was separated by 12% SDS-PAGE and transferred to polyvinylidene difluoride membranes (EMD Millipore, Billerica, MA, USA). The membranes were blocked using Blocking Buffer (cat. no. P0023B; Beyotime Institute of Biotechnology) for 2 h at room temperature. Proteins were probed using specific primary antibodies at 4˚C overnight, followed by incubation with secondary antibodies at room temperature for 1 h. Specific primary antibodies against pro-caspase-3 (ab44976; 1:500), cleaved caspase-3 (ab13847; 1:500) and cleaved poly ADP-ribose polymerase (PARP; ab32064; 1:2,000) were purchased from Abcam (Cambridge, UK). Secondary antibodies against β-actin (ab8227; 1:2,000) and Larmin A (ab26300; 1:1,000) used in this study were horseradish peroxidase (HRP) conjugated goat anti-rabbit IgG or anti-mouse IgG-HRP (Beyotime Institute of Biotechnology). β-actin and Larmin A were used as internal controls to normalize results. Signals were monitored using a chemiluminescent substrate (KPL, Inc., Gaithersburg, MD, USA). Following electrophoresis, gray values were analyzed using Quantity One v4.4.0.36 software (Bio-Rad Laboratories, Inc., Hercules, CA, USA).
Caspase-3 activity. The activity of caspase-3 was conducted using a commercial ELISA kit (cat. no. HC079; Shanghai Gefan Biotechnology Co., Ltd., Shanghai, China) according to the manufacturer's protocols. In brief, cells (1x10 6 ) were resuspended in 50 µl lysis buffer (Shanghai Gefan Biotechnology Co., Ltd.) and incubated for 1 h in an ice bath. The supernatant was collected following centrifugation for 10 min at 800 x g at room temperature, following which a colorimetric reagent was added and incubated for 4 h at 37˚C. The colorimetric product was monitored using an ELISA reader at a wavelength of 405 nm.
Apoptosis detection using flow cytometry.
A total of 1x10 6 cells were washed with PBS and resuspended in binding buffer containing Annexin V-APC and propidium iodide, and incubated at 20-25˚C for 10-20 min (Beyotime Institute of Biotechnology). The samples were analyzed using a FACScan flow cytometer (BD Biosciences, Franklin Lakes, NJ, USA). The percentage of apoptotic cells in a 10,000-cell cohort was determined using flow cytometry.
NF-κB P65 activity.
Following treatment, nuclear extracts were isolated using the Nuclear Extract kit according to the manufacturer's protocols (Active Motif, Carlsbad, CA, USA; cat. no. 40010). The activity of NF-κB p65 was assessed using an ELISA kit (cat. no. 40596; Active Motif).
Statistical analysis.
Values are presented as the mean ± standard deviation. Statistical comparisons between cell lines were performed using one-way analysis of variance, followed by Dunnett's t-test. GraphPad Prism 7.03 software (GraphPad Software Inc., La Jolla, CA, USA) was used to analyze experimental data and a P<0.05 was considered to indicate a statistically significant difference.
Results

Icariin prevents cytokine-induced loss of cell viability.
To assess the therapeutic potential of icariin in rat pancreatic β cells, the viability of cultured RINm5F cells was initially examined. As presented in Fig. 1 , treatment with icariin up to 10 µM did not result in a significant loss of cell viability. Next, whether icariin protected RINm5F cells from cytokine toxicity was investigated. Treatment with cytokines IL-1β and IFN-γ significantly reduced the cell viability to 49.9±5.2% of the control value (Fig. 1) . Pretreatment with icariin significantly abrogated the cytotoxic effects of cytokines on RINm5F cells in a concentration-dependent manner.
Icariin prevents cytokine-induced NO production. NO production was significantly increased following 24 h treatment with cytokines ( Fig. 2A) . However, the cytokine-induced NO production was effectively inhibited by treatment with 10 µM icariin ( Fig. 2A) . To investigate the underlying mechanisms responsible for the effects of icariin, RT-qPCR and western blotting were performed to measure the expression of iNOS at the mRNA and protein level, respectively. Treatment with IL-1β and IFN-γ significantly increased the expression of iNOS, while icariin treatment significantly ameliorated this increase at the mRNA and protein level (Fig. 2) .
Icariin prevents cytokine-induced apoptosis. Cytokines are able to promote β-cell death through apoptosis and necrosis (25) . Caspase-3 serves a pivotal role in the apoptotic signaling pathway, and so the activation status of caspase-3 was assessed in the present study. Treatment with IL-1β and IFN-γ increased the activity of caspase-3 and cell apoptosis in RINm5F cells, while icariin effectively reversed these effects (Fig. 3) . The activation of apoptotic signaling was also confirmed by western blotting (Fig. 3B) . Cleaved caspase-3 is the main marker of cell apoptosis (26) , and so its expression was assessed. As presented in Fig. 3B , IL-1β and IFN-γ were able to activate caspase-3 and increase the cleavage of PARP in RINm5F cells, while treatment with icariin reduced cleaved caspase-3 and cleaved PARP levels in cytokine-stimulated cells.
Icariin suppresses the cytokine-induced activation of NF-κB.
NF-κB is a key transcription factor that induces iNOS and regulates subsequent NO production (27) . The results of a previous study by our group demonstrated that NF-κB was activated by cytokines or oxidative stress (28) . Based on this, it was investigated whether icariin affects the cytokine-induced activation and translocation of NF-κB from the cytosol to the nucleus in RINm5F cells. NF-κB and the nuclear translocation of p65, a key subunit of the NF-κB complex, were significantly promoted by treatment with IL-1β and IFN-γ compared with the control (Fig. 4) . In contrast, icariin pretreatment markedly suppressed the cytokine-stimulated activation and nuclear translocation of NF-κB. In summary, these data suggest that icariin may downregulate iNOS expression via inhibiting the cytokine-stimulated activation of NF-κB.
Discussion
Icariin is a biologically active flavonoid with a favorable therapeutic profile in metabolic syndrome (29, 30) . Notably, icariin has been reported to ameliorate streptozocin-induced rat diabetic retinopathy and nephropathy (31, 32) . A previous study demonstrated that icariin could serve as a peroxisome proliferator-activated receptor α agonist, which activates gene expression associated with lipid metabolism in the liver to contribute towards diabetes management (33) . In the present study, it was revealed that icariin is able to prevent cytokine-induced β-cell death, which is an important cause of T1DM.
Inflammation is the primary cause of T1DM as well as a direct cause of a number of diabetic complications (34) . An acute, intense inflammatory response triggers T1DM It has therefore been hypothesized that anti-inflammatory agents may be an effective clinical treatment for patients with T1DM. A number of in vivo and in vitro studies have confirmed the anti-inflammatory effect of icariin, including in the brain, heart, bones and airways (22, 23, (39) (40) (41) (42) (43) (44) (45) (46) (47) (48) (49) (50) . The present study demonstrated that icariin prevents viability loss in rat pancreatic β cells, as well as suppressing cytokine-induced NO production and apoptosis activation. These results suggest that icariin may interfere with the inflammatory response and resulting pancreatic β cell death during T1DM. Furthermore, a key factor in cytokine-induced pancreatic β-cell damage is NF-κB. In vivo studies of transgenic mice revealed that NF-κB inhibition is a protective mechanism against cytokine-induced apoptosis in pancreatic β-cells (28) . In addition, the use of A20-overexpressing islets to abrogate NF-κB signaling during islet transplantation reduces the number of islets required to achieve euglycemia in diabetic recipients (51) . Therefore, suppression of the NF-κB pathway may also be a novel strategy for delaying the progression of T1DM. The regulatory role of icariin on NF-κB has been reported, however it may vary between different cell types (20) . Xu and Huang (52) demonstrated that icariin could increase the expression of endothelial NOS in human endothelial cells, which was implicated in the activation of NF-κB (53) . In contrast, icariin was able to abrogate the effects of LPS on neuroinflammation, lung inflammation, osteoclast differentiation and bone resorption via decreasing NF-κB activity (23, 49, 54, 55) . It has also been reported that icariin inhibits NF-κB activity in a wide range of cancerous cells (56) (57) (58) (59) . The results of the present study demonstrated that icariin suppresses the cytokine-induced activation of NF-κB in rat pancreatic β cells. It is likely that icariin exerts cell-specific regulatory effects and only suppresses high levels of NF-κB activity in tumor cells or cells stimulated by inflammatory cytokines.
The results of the present study demonstrate that icariin abrogates the pro-apoptotic effect of cytokines and significantly suppresses NF-κB activation in rat pancreatic β-cells. Despite being used extensively as a model for the human pancreas, the physiology of rat pancreatic β cells does not perfectly mimic that of primary cells (60) . The RINm5F cells used in the present study have limitations in terms of glucose sensitivity, transport and phosphorylation (60, 61) . Therefore, experiments utilizing human pancreatic cells and in vivo analysis are required to confirm these findings. Nevertheless, the results of the present study suggest that icariin may have potential as a therapeutic agent against T1DM. 
